ÂÜÀòÂÒÂ×

Michael Morabito is the current Managing Director at Solebury Trout. Prior to this, they were the Senior Research Analyst - SMid-Cap Biotechnology at Chardan from November 2019 to May 2021. From November 2016 to October 2019, they were the Vice President Equity Research and Senior Analyst - SMid-Cap Biotech at Credit Suisse with a coverage universe of ICPT, MRTX, MGNX, and CRVS. Prior to that, they were the Scientific Administrator - Genetic Medicine at Weill Cornell Medicine from July 2016 to November 2016 where they facilitated the development and/or continual operation of 10-15 projects with 4 companies and the NIH. Michael was also the Associate Research Scientist at Columbia University Medical Center from November 2010 to June 2016. Michael Morabito began their career as a Post-doctoral Fellow / Graduate Student at Vanderbilt University Medical Center from August 2000 to November 2010.

Michael Morabito holds a Ph.D. in Neuroscience from Vanderbilt University. Michael also holds a BA in Biology from the University of Virginia. Morabito is certified by the Financial Industry Regulatory Authority (FINRA) in Series 7, Series 63, Series 86, and Series 87.

Their manager is Jeff Grossman, Co-CEO. Michael Morabito works with Jack Yauch - Senior Associate, Matthew Murphy - Analyst, and David Buck - SVP.